ARAY (ARAY) Stock Analysis

Verdict: AVOID

Crushing debt of $183.9M and declining revenues make Accuray a speculative micro-cap squeeze play despite short-term price surges.

Investment score: 27/100

Is ARAY Stock Worth Reviewing? AI Model Thesis

The model assesses Accuray as an unviable buy-and-hold candidate due to deteriorating operating margins (-7.2%) and severe leverage, recommending an AVOID stance.

Should You Buy or Sell ARAY Stock? Model Reasoning

Accuray trades at an ultra-low P/S of 0.09x but faces severe fundamental distress with a $183.9M debt burden against $41.7M total equity, alongside revenue shrinking -12.3% year-over-year. Despite a +39.4% single-day spike to $0.2998, persistent cash burn (-$12.8M FCF) and recent analyst downgrades reinforce a high risk of shareholder dilution or restructuring.

ARAY Fair Value & Price Target — AI Valuation

  • Model Assumptions: ["Gross margin recovers from 27.7% in FY2026 toward 32-34% over the next 12-24 months.","Annual cash burn remains bounded below $15M, preserving the current $41.2M cash balance over a ~32-month runway without immediate emergency equity dilution.","Revenue stabilizes around consensus $410M in FY2027 (0.09x P/S vs historical peer average of 1.5x-2.0x EV/Sales)."]

ARAY Risk & Opportunity Analysis

Key Investment Risks

  • Extreme debt burden of $183.9M against total equity of $41.7M creates severe debt covenant and refinancing default risk. — With $41.2M in cash and -$12.8M annual FCF burn, debt service costs could force aggressive equity dilution or bankruptcy restructuring before debt maturities.
  • Revenue contraction of -12.3% YoY in FY2026 highlights competitive market share loss to Varian and Elekta. — Hospitals delaying capital expenditure on high-cost radiosurgery capital equipment could reduce revenues below $400M in FY2027.
  • NASDAQ delisting threat due to sustained trading below $1.00 per share. — Trading at $0.30 requires a reverse stock split to maintain listing compliance, which historically triggers additional institutional selling pressure.
  • Analyst capitulation and loss of Wall Street coverage. — With Jefferies and BTIG downgrading ARAY to Hold/Neutral in May 2026, institutional liquidity will dry up further, increasing bid-ask spread friction.

Growth Opportunities & Upside Drivers

  • CyberKnife and Radixact installed base service revenues provide recurring cash inflows. — High-margin maintenance contracts help soften equipment delivery volatility, generating baseline cash to partially offset operating burn of -$12.8M FCF.
  • Depressed valuation of 0.09x P/S and 0.74x P/B presents turnaround upside if debt is restructured. — If management restructures debt or achieves operating profitability by FY2028 as revenue stabilizes near $420M, EV expansion could drive multi-bagger returns.
  • Potential strategic acquisition candidate for a larger MedTech conglomerate. — At a sub-$40M market cap, a peer could acquire Accuray proprietary motion-tracking IP and global radiation base at a substantial premium.
  • Short-term momentum surges triggered by low float and extreme short interest. — Volume spikes like the recent 131x surge allow agile traders to capture 20%-40% quick tactical rallies off historic support near $0.215.

ARAY Action Plan — Entry, Exit and Stop Loss from the Model View

moderate

    aggressive

      conservative

        Frequently Asked Questions About ARAY (ARAY)

        Is ARAY stock a good investment?

        The cached TradeMates AI model rates ARAY as AVOID with an investment score of 27/100. The model assesses Accuray as an unviable buy-and-hold candidate due to deteriorating operating margins (-7.2%) and severe leverage, recommending an AVOID stance. This is algorithmic model output, not personal investment advice.

        Does ARAY pay a dividend?

        The cached stock data on this page does not show a positive dividend yield for ARAY. Dividend status can change, so verify the latest company filings before relying on income assumptions.

        What does ARAY stock do?

        Accuray designs, manufactures, and services radiation oncology systems (CyberKnife, TomoTherapy/Radixact) for hospital and cancer center clients globally. Revenue is split between Capital Equipment sales (hardware/software) and recurring Post-Sale Services (service contracts, maintenance, training).

        What is ARAY stock's price target?

        This cached page does not contain a precise model fair value for ARAY.

        Is ARAY stock a buy?

        The TradeMates model verdict for ARAY is AVOID with an investment score of 27/100. Treat this as a model signal to review, not a personal buy recommendation.

        Is ARAY a good dividend stock?

        ARAY is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

        View the full interactive analysis